Data emerging from preclinical and clinical studies are starting to delineate a scenario in which HIF-1α and HIF-2α may operate differently in relation to CLD progression, with a recent focus mainly on progressive NAFLD and ALD. This evidence concerns the gene HIF1A and metabolic dysfunction-associated steatotic liver disease.